<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of this study was to compare <z:mp ids='MP_0001914'>bleeding</z:mp> and re-<z:mp ids='MP_0005048'>thrombosis</z:mp> in <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> (PAPS), mitral valve replacement (MVR) and inherited <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> (IT) at different oral anticoagulation intensities </plain></SENT>
<SENT sid="1" pm="."><plain>It entailed a prospective 8-year follow-up on 67 patients with PAPS, 89 with IT and 24 with MVR </plain></SENT>
<SENT sid="2" pm="."><plain>Anticardiolipin (aCL) antibodies detected by Elisa and <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> by clotting assays </plain></SENT>
<SENT sid="3" pm="."><plain>At INR 2-3 minor <z:mp ids='MP_0001914'>bleeding</z:mp> rate was higher in MVR (33.3) than PAPS (10.9) and IT (4.2)(p&lt;0.0001) </plain></SENT>
<SENT sid="4" pm="."><plain>At INR 3-4 minor <z:mp ids='MP_0001914'>bleeding</z:mp> rate was higher in PAPS (142) than IT (33.3) and MVR (5.8)(p&lt;0.0001) </plain></SENT>
<SENT sid="5" pm="."><plain>At either INR major <z:mp ids='MP_0001914'>bleeding</z:mp> rate were not significantly different across the three groups, but in PAPS major and minor <z:mp ids='MP_0001914'>bleeding</z:mp> rates were superior at INR 3-4 than INR 2-3 (p=0.02 and p&lt;0.0001) </plain></SENT>
<SENT sid="6" pm="."><plain>Re-<z:mp ids='MP_0005048'>thrombosis</z:mp> rate was higher in PAPS than IT at INR 2-3 (4.0 vs 0.35) (p=0.01) and at INR 3-4 (10.5 vs. nil) </plain></SENT>
<SENT sid="7" pm="."><plain>The hazard ratio for re-<z:mp ids='MP_0005048'>thrombosis</z:mp> between PAPS and IT was 13 (95% IC 1.6-102.2, p=0.015) </plain></SENT>
<SENT sid="8" pm="."><plain>By regression analysis, baseline IgG aCL titre (&gt;80 GPL) p=0.001) and male sex (p=0.03) independently predicted re-<z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, in PAPS, high intensity oral anticoagulation was not superior to conventional intensity in preventing re-<z:mp ids='MP_0005048'>thrombosis</z:mp> but was offset by greater <z:mp ids='MP_0001914'>bleeding</z:mp> rates </plain></SENT>
<SENT sid="10" pm="."><plain>Male sex and elevated baseline IgG aCL predicted rethrombosis in PAPS that is 13-fold more re-thrombogenic than IT </plain></SENT>
</text></document>